PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. (PROSTAC)

January 23, 2020 updated by: Centro Nacional de Investigaciones Oncologicas CARLOS III

Prospective Multi-centre Study of Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel or Cabazitaxel.

PROSTAC is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with docetaxel or cabazitaxel

Study Overview

Status

Unknown

Conditions

Detailed Description

This study is a prospective biomarker study of patients with mCRPC undergoing treatment with docetaxel or cabazitaxel as standard of care treatment. The participants will undergo serial pre- and post-therapy blood collection for biomarker analysis as part of the primary objective of the study.

Study Type

Observational

Enrollment (Anticipated)

402

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • A Coruna, Spain, 15009
        • Fundacion Centro Oncologico de Galicia
      • Barcelona, Spain, 08035
        • Hospital Universitario Vall d'Hebron
      • Ciudad Real, Spain, 13005
        • Hospital de Ciudad Real
      • Cordoba, Spain, 14004
        • Hospital Universitario Reina Sofia
      • Granada, Spain, 18014
        • Hospital Universitario Virgen de las Nieves
      • Guadalajara, Spain, 19002
        • Hospital Universitario de Guadalajara
      • Madrid, Spain, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Spain, 28040
        • Hospital Universitario Clinico San Carlos
      • Madrid, Spain, 28007
        • Hospital Universitario Gregorio Marañon
      • Madrid, Spain, 28050
        • Centro Integral Oncologico Clara Campal
      • Madrid, Spain, 28029
        • Coordination PROCURE-Centro Nacional de Investigaciones Oncologicas
      • Malaga, Spain, 29010
        • Anatomical Pathology PROCURE
      • Malaga, Spain, 29010
        • Hospital Regional Universitario Virgen de la Victoria
      • Murcia, Spain, 30008
        • Hospital Morales Messeguer
      • Málaga, Spain, 29010
        • Hospital Universitario Virgen de la Victoria
      • Palma de Mallorca, Spain, 07120
        • Hospital Son Espases
      • Pontevedra, Spain, 36002
        • Complejo Hospitalario de Pontevedra
      • Valencia, Spain, 46026
        • Hospital Universitario La Fe
    • A Coruña
      • Santiago de Compostela, A Coruña, Spain, 15706
        • Hospital Universitario de Santiago
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spain, 08907
        • ICO l'Hospitalet
      • Manresa, Barcelona, Spain, 08243
        • Hospital Althaia Manresa
    • Cádiz
      • Jerez de la Frontera, Cádiz, Spain, 11407
        • Hospital de Especialidades de Jerez de La Frontera
    • Málaga
      • Marbella, Málaga, Spain, 29603
        • Hospital Costa del Sol
    • Navarra
      • Pamplona, Navarra, Spain, 31008
        • Complejo Hospitalario de Navarra
    • Tenerife
      • La Laguna, Tenerife, Spain, 38320
        • Hospital Universitario de Canarias

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

Castration-Resistant Prostate Cancer patients

Description

Inclusion Criteria:

  1. Male age ≥ 18 years
  2. Histologically confirmed adenocarcinome of the prostate
  3. ECOG Performance Status ≤ 2
  4. Castration resistance must be documented with surgical or medical castration with serum testosterone < 50 ng/mL (< 2.0 nM).
  5. Men diagnosed with at least one metastatic lesion on CT or bone scan.
  6. Documented biochemical and/or radiographic progression to previous treatment according to PCWG2 criteria.
  7. Patients who are candidates for standard of care treatment with docetaxel 75mg/m2 every 3 weeks or cabazitaxel 20-25mg/m2 every 3 weeks intravenously.
  8. Availability of formalin-fixed paraffin-embedded blocks from the prostate biopsy and/or radical prostatectomy.
  9. Acceptable hematological, hepatic and renal functions.

Exclusion Criteria:

  1. Previous cancer diagnosis, except those patients who had a localized malignant tumour and who are five years cancer-free or those diagnosed with skin cancers (of non-melanoma type) or excised in situ carcinomas.
  2. Any condition or reason that, in the opinion of the Investigator, interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of safety data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Docetaxel
Docetaxel 75mg/m2 IV every 3 weeks
Cabazitaxel
Cabazitaxel 20-25mg/m2 IV every 3 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To validate the prognostic value of the gene-expression signature from peripheral blood described by Olmos et al (Lancet Oncol 2012) on overall survival of mCRPC patients
Time Frame: 48 months
48 months

Secondary Outcome Measures

Outcome Measure
Time Frame
To analyze the prognostic value of the gene-expression signature described by Olmos et al on biochemical and radiological progression-free survival
Time Frame: 48 months
48 months
To analyze the prognostic value of early changes in the gene-expression signature described by Olmos et al
Time Frame: 48 months
48 months
To compare the prognostic value of the gene-expression signature described by Olmos et al versus the gene-expression signature described by Ross et al (Lancet Oncol, 2012)
Time Frame: 48 months
48 months
To validate the prognostic value of classical nomograms designed to assess the outcomes of mCRPC patients in these both cohorts of patients
Time Frame: 48 months
48 months
To analyze the prognostic value of TMPRSS2-ERG rearrengement and PTEN loss in these cohorts
Time Frame: 48 months
48 months
To analyze the prognostic value of AR splicing variants, serum chromogranine and serum testosterone levels measured by ultrasensitive method in these both cohorts of patients
Time Frame: 48 months
48 months
To correlate the presence of somatic and/or germinal mutations with the outcomes of these patients
Time Frame: 48 months
48 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centro Nacional de Investigaciones Oncologicas CARLOS III

Investigators

  • Principal Investigator: David Olmos, MD, PhD, Head of Prostate Cancer Clinical Research Unit CNIO

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2014

Primary Completion (Actual)

April 1, 2018

Study Completion (Anticipated)

December 1, 2020

Study Registration Dates

First Submitted

February 9, 2015

First Submitted That Met QC Criteria

February 12, 2015

First Posted (Estimate)

February 13, 2015

Study Record Updates

Last Update Posted (Actual)

January 27, 2020

Last Update Submitted That Met QC Criteria

January 23, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CNI-DOC-2014-02
  • CNIO-CP-02-2014 (Other Identifier: CNIO)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Advanced Prostate Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe